Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 19/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 19/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 19/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 18/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 18/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4468911 | 0.85 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL6770906 | 0.80 | SLC6A4 (0.53) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL8554659 | 0.79 | HPGD (0.45) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL758733 | 0.79 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL4872153 | 0.79 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL4468913 | 0.78 | TNF (0.44) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL8369503 | 0.78 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL6770177 | 0.77 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL7313213 | 0.77 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL16649632 | 0.76 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592344-B2 | NK1 and NK2-antagonists and compositions and methods of using the same | SOLVAY PHARMACEUTICALS GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| EP-1954678-A1 | NOVEL NK1 AND NK2 ANTAGONISTS | Solvay Pharmaceuticals GmbH (DE) | 2008-08-13 | — | — | EP | disclosed |
| US-20070149537-A1 | NK1 and NK2-antagonists and compositions and methods of using the same | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-06-28 | — | — | US | disclosed |
| WO-2007063086-A1 | NOVEL NK1 AND NK2 ANTAGONISTS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149537-A1 | NK1 and NK2-antagonists and compositions and methods of using the same | HRH2, PROKR2, BDKRB2 | SLC6A2 1388/4885SLC6A4 2566/4885SLC6A3 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.